See more : Brampton Brick Limited (BBL-A.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Vericel Corporation (VCEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vericel Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Formuepleje Globale Aktier (FPIGA.CO) Income Statement Analysis – Financial Results
- Mastercard Incorporated (MA.NE) Income Statement Analysis – Financial Results
- Japan Aviation Electronics Industry, Limited (JPAVF) Income Statement Analysis – Financial Results
- Isofol Medical AB (publ) (ISOFOL.ST) Income Statement Analysis – Financial Results
- System Research Co.,Ltd. (3771.T) Income Statement Analysis – Financial Results
Vericel Corporation (VCEL)
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 197.52M | 164.37M | 156.18M | 124.18M | 117.85M | 90.86M | 63.92M | 54.38M | 51.17M | 28.80M | 19.00K | 21.00K | 18.00K | 89.00K | 182.00K | 522.00K | 685.00K | 863.00K | 909.00K | 1.30M | 844.00K | 877.00K | 899.00K | 1.15M | 881.00K | 249.00K | 400.00K | 1.60M |
| Cost of Revenue | 61.94M | 54.58M | 50.16M | 39.95M | 37.57M | 32.16M | 30.35M | 28.31M | 26.47M | 17.29M | 4.00K | 6.00K | 4.00K | 34.00K | 112.00K | 56.00K | 29.00K | 11.00K | 148.00K | 280.00K | 893.00K | 202.00K | 13.00K | 926.00K | 6.00K | 0.00 | -500.00K | 9.60M |
| Gross Profit | 135.58M | 109.79M | 106.03M | 84.23M | 80.28M | 58.70M | 33.57M | 26.08M | 24.70M | 11.50M | 15.00K | 15.00K | 14.00K | 55.00K | 70.00K | 466.00K | 656.00K | 852.00K | 761.00K | 1.02M | -49.00K | 675.00K | 886.00K | 224.00K | 875.00K | 249.00K | 900.00K | -8.00M |
| Gross Profit Ratio | 68.64% | 66.80% | 67.88% | 67.83% | 68.12% | 64.60% | 52.52% | 47.95% | 48.27% | 39.95% | 78.95% | 71.43% | 77.78% | 61.80% | 38.46% | 89.27% | 95.77% | 98.73% | 83.72% | 78.49% | -5.81% | 76.97% | 98.55% | 19.48% | 99.32% | 100.00% | 225.00% | -500.00% |
| Research & Development | 21.04M | 19.94M | 16.29M | 13.02M | 30.39M | 13.60M | 12.94M | 15.30M | 18.89M | 21.26M | 15.10M | 26.03M | 21.33M | 12.66M | 11.29M | 15.25M | 11.44M | 9.48M | 7.21M | 6.29M | 5.65M | 5.43M | 4.98M | 6.29M | 10.87M | 15.50M | 13.40M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49.01M | 35.61M | 27.39M | 22.48M | 13.77M | 5.88M | 7.75M | 0.00 | 5.20M | 4.95M | 6.44M | 8.68M | 9.10M | 5.97M | 5.39M | 4.02M | 3.53M | 2.48M | 3.36M | 2.84M | 2.86M | 2.00M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 121.00M | 106.90M | 97.59M | 68.84M | 61.14M | 49.01M | 35.61M | 27.39M | 22.48M | 13.77M | 5.88M | 7.75M | 7.72M | 5.20M | 4.95M | 6.44M | 8.68M | 9.10M | 5.97M | 5.39M | 4.02M | 3.53M | 2.48M | 3.36M | 2.84M | 2.86M | 2.00M | 2.10M |
| Other Expenses | 0.00 | 95.00K | 52.00K | -13.00K | -20.00K | -31.00K | -92.00K | -10.00K | 47.00K | -2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.21M | 5.64M | 5.64M | 0.00 | 325.00K | 0.00 | 0.00 | 500.00K | 400.00K |
| Operating Expenses | 142.04M | 126.85M | 113.88M | 81.86M | 91.53M | 62.61M | 48.55M | 42.68M | 41.37M | 35.04M | 20.98M | 33.78M | 29.05M | 17.86M | 16.24M | 21.69M | 20.13M | 18.59M | 13.18M | 11.68M | 9.66M | 8.96M | 7.47M | 9.98M | 13.71M | 18.36M | 15.90M | 2.50M |
| Cost & Expenses | 203.98M | 181.42M | 164.04M | 121.81M | 129.10M | 94.77M | 78.91M | 70.99M | 67.84M | 52.33M | 20.98M | 33.78M | 29.06M | 17.89M | 16.35M | 21.74M | 20.15M | 18.60M | 13.33M | 11.96M | 10.56M | 9.16M | 7.48M | 10.90M | 13.71M | 18.36M | 15.40M | 12.10M |
| Interest Income | 4.63M | 1.34M | 224.00K | 691.00K | 1.61M | 897.00K | 14.00K | 8.00K | 36.00K | 24.00K | 16.00K | 50.00K | 53.00K | 115.00K | 296.00K | 1.17M | 1.26M | 594.00K | 594.00K | 169.00K | 134.00K | 342.00K | 364.00K | 364.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 600.00K | 366.00K | 4.00K | 6.00K | 8.00K | 1.73M | 1.11M | 314.00K | 9.00K | 6.00K | 11.00K | 12.00K | 10.00K | 40.00K | 73.00K | 73.00K | 84.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.63M | 8.20M | 7.39M | 6.83M | 4.53M | 1.43M | 1.61M | 1.89M | 1.59M | 752.00K | 489.00K | 649.00K | 647.00K | 592.00K | 704.00K | 351.00K | -47.00K | 191.00K | 99.00K | 125.00K | 119.00K | 126.00K | 102.00K | 325.00K | 226.00K | 377.00K | 500.00K | 400.00K |
| EBITDA | 2.86M | -11.64M | -4.61M | 9.88M | -5.13M | -4.98M | -14.57M | -17.37M | -14.74M | -19.16M | -15.12M | -28.81M | -19.01M | -30.15M | -17.80M | -15.47M | -21.22M | -19.47M | -17.73M | -12.42M | -10.36M | -9.71M | -8.16M | -6.48M | -9.43M | -12.62M | -17.75M | -14.50M |
| EBITDA Ratio | 1.45% | -9.50% | -4.85% | 2.46% | -8.19% | -3.35% | -23.56% | -30.54% | -32.42% | -81.65% | -107,678.95% | -157,433.33% | -209,566.67% | -19,339.33% | -8,497.25% | -3,997.70% | -2,842.19% | -2,032.68% | -1,356.44% | -808.91% | -1,136.73% | -929.87% | -720.47% | -819.91% | -1,571.28% | -7,120.48% | -3,800.00% | -675.00% |
| Operating Income | -6.46M | -17.06M | -7.85M | 667.00K | -11.25M | -3.91M | -14.98M | -19.25M | -16.67M | -23.53M | -20.96M | -33.76M | -29.04M | -17.80M | -16.17M | -21.22M | -19.47M | -17.73M | -12.42M | -10.66M | -9.71M | -8.28M | -6.58M | -9.75M | -12.83M | -18.11M | -15.00M | -10.50M |
| Operating Income Ratio | -3.27% | -10.38% | -5.03% | 0.54% | -9.55% | -4.30% | -23.44% | -35.39% | -32.58% | -81.73% | -110,336.84% | -160,761.90% | -161,333.33% | -20,004.49% | -8,884.07% | -4,064.94% | -2,842.19% | -2,054.81% | -1,366.01% | -818.51% | -1,150.83% | -944.24% | -731.81% | -848.17% | -1,456.53% | -7,271.89% | -3,750.00% | -656.25% |
| Total Other Income/Expenses | 4.10M | 1.07M | 272.00K | 672.00K | 1.59M | -4.23M | -2.30M | -321.00K | 331.00K | 3.61M | 5.34M | 4.29M | 9.37M | -20.37M | 1.86M | 223.00K | 1.09M | 1.88M | 1.26M | 606.00K | 169.00K | 134.00K | -1.11M | 364.00K | 1.24M | 0.00 | 3.85M | 5.20M |
| Income Before Tax | -2.37M | -15.99M | -7.58M | 3.04M | -9.67M | -8.14M | -17.29M | -19.57M | -16.34M | -19.92M | -15.62M | -29.47M | -19.71M | -17.73M | -15.95M | -20.13M | -16.48M | -11.81M | -12.41M | -10.49M | -9.58M | -7.94M | -9.39M | -9.39M | -11.60M | 0.00 | -14.30M | -9.80M |
| Income Before Tax Ratio | -1.20% | -9.73% | -4.85% | 2.45% | -8.20% | -8.96% | -27.04% | -35.98% | -31.93% | -69.18% | -82,221.05% | -140,352.38% | -109,505.56% | -19,920.22% | -8,761.54% | -3,856.90% | -2,405.11% | -1,368.60% | -1,364.69% | -805.53% | -1,134.95% | -905.25% | -1,044.49% | -816.52% | -1,316.12% | 0.00% | -3,575.00% | -612.50% |
| Income Tax Expense | 814.00K | 721.00K | -111.00K | 180.00K | -1.76M | 3.36M | 1.12M | 2.64M | -257.00K | -3.60M | -5.34M | -4.25M | -18.71M | -115.00K | -296.00K | -1.09M | -1.83M | -1.26M | -618.00K | -169.00K | -134.00K | -342.00K | -653.00K | -364.00K | -3.04M | -874.00K | -1.40M | -1.30M |
| Net Income | -3.18M | -16.71M | -7.47M | 2.86M | -7.91M | -8.14M | -17.29M | -19.57M | -16.34M | -19.92M | -15.62M | -29.47M | -19.67M | -17.73M | -15.95M | -20.13M | -17.59M | -16.48M | -11.81M | -10.49M | -9.58M | -7.94M | -5.93M | -9.39M | -11.03M | -17.23M | -14.30M | -9.90M |
| Net Income Ratio | -1.61% | -10.17% | -4.78% | 2.31% | -6.71% | -8.96% | -27.04% | -35.98% | -31.93% | -69.18% | -82,221.05% | -140,352.38% | -109,266.67% | -19,920.22% | -8,761.54% | -3,856.90% | -2,568.47% | -1,909.04% | -1,299.34% | -805.53% | -1,134.95% | -905.25% | -659.18% | -816.52% | -1,251.76% | -6,920.88% | -3,575.00% | -618.75% |
| EPS | -0.07 | -0.35 | -0.16 | 0.06 | -0.18 | -0.20 | -0.52 | -0.85 | -0.69 | -1.71 | -5.18 | -14.31 | -10.19 | -14.34 | -17.84 | -24.95 | -23.55 | -24.79 | -20.20 | -22.77 | -30.06 | -30.16 | -27.86 | -64.36 | -115.01 | -206.34 | -203.20 | -171.20 |
| EPS Diluted | -0.07 | -0.35 | -0.16 | 0.06 | -0.18 | -0.20 | -0.52 | -0.85 | -0.69 | -1.71 | -5.18 | -14.31 | -10.19 | -14.34 | -17.84 | -24.95 | -23.55 | -24.79 | -20.20 | -22.77 | -30.06 | -30.16 | -27.86 | -64.36 | -115.01 | -206.34 | -203.20 | -171.20 |
| Weighted Avg Shares Out | 47.59M | 47.13M | 46.47M | 45.22M | 44.18M | 40.24M | 33.35M | 23.09M | 23.76M | 11.64M | 3.02M | 2.06M | 1.93M | 1.24M | 893.85K | 807.00K | 747.02K | 664.46K | 584.63K | 460.64K | 318.65K | 263.26K | 212.69K | 145.90K | 95.89K | 83.52K | 70.37K | 57.83K |
| Weighted Avg Shares Out (Dil) | 47.59M | 47.13M | 46.47M | 47.28M | 44.18M | 40.24M | 33.36M | 23.09M | 23.76M | 11.64M | 3.02M | 2.06M | 1.93M | 1.24M | 893.85K | 807.00K | 747.02K | 664.46K | 584.63K | 460.64K | 318.65K | 263.26K | 212.69K | 145.90K | 95.89K | 83.52K | 70.37K | 57.83K |
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Here's Why Momentum in Vericel (VCEL) Should Keep going
Vericel (VCEL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Vericel Corporation (VCEL) Q3 2024 Earnings Conference Call Transcript
MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Burns - Vice President of Finance & Investor Relations Nick Colangelo - Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call...
Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates
Vericel Corporation (VCEL) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago.
Vericel Reports Third Quarter 2024 Financial Results
Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third Quarter Conference Call Today at 8:30am Eastern Time...
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2024 financial results on Thursday, November 7,...
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in...
Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration Targets the Largest Segment of MACI's $3 Billion Addressable Market CAMBRIDGE, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine...
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers CAMBRIDGE, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced...
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Growth...
Source: https://incomestatements.info
Category: Stock Reports